CytomX Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDCytomX Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 94), indicating clear outperformance against the broad market. Earnings contraction of 234% provides fundamental context to the price action. Investors should exercise caution due to high volatility (98% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $5.56 | -3.41% | BELOW |
| 50 SMA | $5.02 | +6.95% | ABOVE |
| 100 SMA | $4.39 | +22.33% | ABOVE |
| 150 SMA | $3.69 | +45.72% | ABOVE |
| 200 SMA | $3.36 | +59.76% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CTMX in an uptrend right now?
CTMX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, CTMX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is CTMX overbought or oversold?
CTMX's RSI (14) is 52. The stock is in neutral territory, neither overbought nor oversold.
Is CTMX outperforming the market?
CTMX has a Relative Strength (RS) Rating of 94 out of 99. Yes, CTMX is a market leader, outperforming 94% of all stocks over the past 12 months.
Where is CTMX in its 52-week range?
CTMX is trading at $5.37, which is 85% of its 52-week high ($6.35) and 84% above its 52-week low ($0.40).
How volatile is CTMX?
CTMX has a Beta of 1.08 and 52-week volatility of 98%. It's more volatile than the S&P 500 - expect bigger swings.